Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Neeraj Agarwal, MD, discusses the role of docetaxel in the frontline setting, the emergence of novel hormonal agents in the paradigm, and efforts being made with combination regimens to potentially treat patients with resistant disease.

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses the implications of the PFS2 data from the TITAN trial in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the need for further drug development in metastatic castration-sensitive prostate cancer.

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

Katie Kerrigan, MD, discusses remaining challenges in the treatment of patients with ROS1-positive non–small cell lung cancer.

Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, University of Utah, discusses quality of life (QoL) with apalutamide (Erleada) in the treatment of patients with metastatic castration-sensitive prostate cancer.

Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.

Neeraj Agarwal, MD, discusses the TITAN trial and the implications in prostate cancer treatment.

Anna Chalmers, MD, discusses the PACIFIC trial and how its impact continues to change the treatment paradigm in stage III non-small cell lung cancer.

Faculty from Huntsman Cancer Institute and Intermountain Healthcare delve into the interesting research efforts being made at their respective institutions.

Shiven B. Patel, MD, MBA, FACP, provides insight into key trials in squamous non–small cell lung cancer and how to apply the data to practice.

Wallace L. Akerley, MD, discusses targeted approaches for patients with non-small cell lung cancer who harbor alterations in MET, RET, and HER2, as well as the importance of broad molecular profiling.

Neeraj Agarwal, MD, discusses the safety profile of the combination of enzalutamide and talazoparib in patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses patient selection in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Neeraj Agarwal, MD, professor of medicine, physician and investigator, director, Genitourinary Oncology Program, Center of Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, discusses the updated results of the JAVELIN Renal 101 trial in advanced renal cell carcinoma (RCC).

Neeraj Agarwal, MD, discusses the recent encouraging data reported in mRCC and highlighted the next steps needed to move the needle forward in this space.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses unmet needs in metastatic renal cell carcinoma (mRCC).

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the combination of lenvatinib (Lenvima) and everolimus in the treatment of patients with metastatic renal cell carcinoma (mRCC).

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.